The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria  Maria Staevska, MD, Todor A.

Slides:



Advertisements
Similar presentations
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Alveolar nitric oxide and asthma control in mild untreated asthma
Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O
Allergen immunotherapy: A practice parameter third update
Pharmacologic rationale for treating allergic and nonallergic rhinitis
Clarification concerning amoxicillin skin testing
Fatty acids, inflammation, and asthma
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
David A. Khan, MD  Journal of Allergy and Clinical Immunology 
Is 9 more than 2 also in allergic airway inflammation?
Desensitization to Chemotherapeutic Agents
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Fatty acids, inflammation, and asthma
Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.
High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.
Keith J. Simons, PhD, Margherita Strolin Benedetti, PhD, F. Estelle R
Hereditary angioedema: Safety of long-term stanozolol therapy
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J
Treatment of chronic autoimmune urticaria with omalizumab
A network-based analysis of the late-phase reaction of the skin
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria 
Nonadherence to Asthma Treatment: Getting Unstuck
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations  Raymond G.
William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P
Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O
Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA 
Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema  Marek L.
Reply Journal of Allergy and Clinical Immunology
The Editors' Choice Journal of Allergy and Clinical Immunology
Phillip Lieberman, MD, Michael Tankersley, MD 
Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation  Leif Bjermer, MD  Journal of Allergy.
Phillip Lieberman, MD, David Golden, MD 
Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management  Scott H. Sicherer, MD, Hugh A. Sampson, MD  Journal.
Biosimilars and drug development in allergic and immunologic diseases
Claus Bachert, MD, PhD, Cezmi A. Akdis, MD 
What is an “eosinophilic phenotype” of asthma?
Medication use in children with asthma in Finland from 1995 to 2006
Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial  Michael Weschta, MD, Dagmar Rimek,
Jeffrey M. Harris, MD, PhD, Christopher R
H. William Kelly, PharmD  Journal of Allergy and Clinical Immunology 
Real-life treatment of cholinergic urticaria with omalizumab
Autophagy: Nobel Prize 2016 and allergy and asthma research
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
Advances in the approach to the patient with food allergy
Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down  Eric D. Bateman, MD, Loretta Jacques, PhD,
One step forward, 2 steps back: The enigma of preschool wheeze
The Editors' Choice Journal of Allergy and Clinical Immunology
Risk of oral food challenges
Benjamin Chaigne, MD, Hervé Watier, MD, PhD 
Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci 
Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis  Iris M. Otani, MD, Arjun A. Anilkumar,
Acid-suppressive drug use in pregnancy and the toddler's asthma risk: A crossover, case-control study  Bianca Mulder, BSc, Catharina Carolina Maria Schuiling-Veninga,
Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study  Maurizio Marogna, MD, Igino Spadolini, MD, Alessandro.
Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G
Measles and immunomodulation
Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J
Macrolide antibiotics and asthma treatment
Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge  Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.
Asthma: The past, future, environment, and costs
Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection  Alexander A. Navarini, MD, PhD, Lars E.
Environmental factors and eosinophilic esophagitis
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Natural history of cow’s milk allergy
Primary prevention of asthma and allergy
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Presentation transcript:

The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria  Maria Staevska, MD, Todor A. Popov, MD, PhD, Tanya Kralimarkova, MD, Cvetelina Lazarova, MD, Steliana Kraeva, MD, Dora Popova, MD, PhD, Diana S. Church, MD, Vasil Dimitrov, MD, PhD, Martin K. Church, PhD, DSc  Journal of Allergy and Clinical Immunology  Volume 125, Issue 3, Pages 676-682 (March 2010) DOI: 10.1016/j.jaci.2009.11.047 Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 The study design with the treatment arms and the crossover step. Deslo, Desloratadine; Levo, levocetirizine. Journal of Allergy and Clinical Immunology 2010 125, 676-682DOI: (10.1016/j.jaci.2009.11.047) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 The number of patients whose symptoms were relieved by levocetirizine (Levo) or desloratadine (Deslo) throughout the 4 weeks of the study. The numbers in parentheses refer to the number of patients who were symptom free on 5 mg (week 1), 10 mg (week 2), 20 mg (week 3), or after the drug switch (week 4). Journal of Allergy and Clinical Immunology 2010 125, 676-682DOI: (10.1016/j.jaci.2009.11.047) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 The cumulative percentage of patients showing differing levels of improvement of urticaria-related discomfort with increasing doses of A. levocetirizine, and B. desloratadine. The green arrows indicate patients with a >90% improvement on 5 mg (low-dose responders), and the red arrows indicate patients with <10% improvement on 20 mg (nonresponders). Journal of Allergy and Clinical Immunology 2010 125, 676-682DOI: (10.1016/j.jaci.2009.11.047) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 The relationship between somnolence and relief from urticaria discomfort for A. levocetirizine and B. desloratadine. Each point represents the change in the VAS scores of somnolence and relief from urticaria discomfort from those at the beginning of the study to those when the patients were taking the highest dose of the drug that they received. Colors of circles for levocetirizine are as follows: 5 mg, pale yellow, 10 mg, mid yellow, and 20 mg, brown (total, 40 patients). Colors of circles for desloratadine are as follows: 5 mg, pale green, 10 mg, mid green, and 20 mg, dark green (total, 38 patients). Journal of Allergy and Clinical Immunology 2010 125, 676-682DOI: (10.1016/j.jaci.2009.11.047) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions